A new study out of the Washington University School of Medicine suggests that a bone-strengthening drug may also help fight off metastatic breast cancer.
According to the study, women who were given the drug in combination with chemotherapy three months before they had surgery experienced a reduction in the number of cancer cells in their bone marrow.
Breast cancer tumors shed cells that spread throughout the body and most often end up in bone tissue.
The study was conducted on women who had been diagnosed with stage two or stage three breast cancer and measured the difference in the reduction of cancer cells in the study groups.
"Because chemotherapy increases bone loss, we would argue that women should receive zoledronic acid at the time of chemotherapy in the presurgical setting," said Dr Rebecca Aft, lead researcher of the study.
Researchers do acknowledge that more needs to be studied regarding the impact of the bone strengthening drug.
The American Cancer Society (ACS) estimates there were over 190,000 new diagnoses of breast cancer in 2009.